plerixafor has been researched along with Liver Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oupicky, D; Sun, M; Ullah, A; Wang, K; Wu, P | 1 |
| Chan, KM; Chen, Y; Chern, GG; Chiang, T; Hsu, FF; Liu, CH; Liu, JY; Liu, YC; Wu, YH | 1 |
2 other study(ies) available for plerixafor and Liver Cirrhosis
| Article | Year |
|---|---|
CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.
Topics: Animals; Apoptosis; Benzylamines; Cell Line; Cell Line, Tumor; Cell Survival; Cyclams; Drug Delivery Systems; Endocytosis; Hepatic Stellate Cells; Heterocyclic Compounds; Humans; Liposomes; Liver Cirrhosis; Mice; p38 Mitogen-Activated Protein Kinases; Pyridones; Rats; Receptors, CXCR4; Signal Transduction; Tissue Distribution; Transforming Growth Factor beta | 2019 |
Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cyclams; Disease Models, Animal; Disease Progression; Hepatic Stellate Cells; Heterocyclic Compounds; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |